GLP1R and diabetes mellitus: Potential beneficial cardiovascular effects might be expected in patients with diabetes receiving both PCSK9 inhibitor therapy as lipid-lowering agent and SGLT2 inhibitors and/or GLP1-RA for diabetes management.